Clinical Trials in Tennessee

Showing 2281-2300 of 20,239 trials

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

NCT01597388

The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant

AstraZeneca99 participantsStarted May 2012

Sarasota, Florida, United States • Detroit, Michigan, United States • Oklahoma City, Oklahoma, United States +2 more locations

RECRUITINGPhase 329 miles

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

NCT06513962

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.

Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm

Children's Oncology Group60 participantsStarted Feb 2025

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Phoenix, Arizona, United States +184 more locations

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

Find Trials by Condition in Tennessee

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Mode Of Ventilation During Critical IllnEss Pilot Trial

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Myositis Interstitial Lung Disease Nintedanib Trial

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Circumferential Compression STITCH Repairs of Complex and Horizontal Cleavage Meniscal Tears

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Lurbinectedin in FET-Fused Tumors

Incomplete Cervical SCI Without Instability